Literature DB >> 21317048

Splicing defects in the CFTR gene: minigene analysis of two mutations, 1811+1G>C and 1898+3A>G.

Gwendal Dujardin1, Diane Commandeur, Catherine Le Jossic-Corcos, Claude Ferec, Laurent Corcos.   

Abstract

BACKGROUND: Cystic fibrosis is caused by mutations of the Cystic Fibrosis Transmembrane conductance Regulator gene (CFTR). Among the 1795 reported mutations, 221 (12.31%) are believed to affect pre-mRNA splicing. Nevertheless, not all splicing mutations have been demonstrated, by functional assays, to affect splicing in living cells.
METHODS: We have used a minigene-based approach, coupled to site-specific mutagenesis, to analyze the effects of presumptive pre-mRNA splicing mutations.
RESULTS: We show here that the intron 11 1811+1G>C and the intron 12 1898+3A>G mutations strongly affected CFTR pre-mRNA splicing. The encoded proteins are predicted to be defective, which would thus participate in the disease phenotype of carrier individuals.
CONCLUSIONS: These results further validate the minigene strategy for the study of presumptive splice mutations, and report unanticipated defects in splicing. Such assays should improve the analysis of genotype-phenotype correlations.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317048     DOI: 10.1016/j.jcf.2010.12.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

1.  Functional analysis of synonymous substitutions predicted to affect splicing of the CFTR gene.

Authors:  Alexandra Scott; Hanna M Petrykowska; Timothy Hefferon; Valer Gotea; Laura Elnitski
Journal:  J Cyst Fibros       Date:  2012-05-14       Impact factor: 5.482

Review 2.  Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.

Authors:  Kevin G Chen; Pingyu Zhong; Wei Zheng; Jeffrey M Beekman
Journal:  Drug Discov Today       Date:  2019-06-04       Impact factor: 7.851

3.  Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites.

Authors:  Melissa Lee; Patrick Roos; Neeraj Sharma; Melis Atalar; Taylor A Evans; Matthew J Pellicore; Emily Davis; Anh-Thu N Lam; Susan E Stanley; Sara E Khalil; George M Solomon; Doug Walker; Karen S Raraigh; Briana Vecchio-Pagan; Mary Armanios; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2017-05-04       Impact factor: 11.025

Review 4.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

Review 5.  Pluripotent Stem Cell Platforms for Drug Discovery.

Authors:  Kevin G Chen; Barbara S Mallon; Kyeyoon Park; Pamela G Robey; Ronald D G McKay; Michael M Gottesman; Wei Zheng
Journal:  Trends Mol Med       Date:  2018-07-11       Impact factor: 11.951

6.  Functional Studies and In Silico Analyses to Evaluate Non-Coding Variants in Inherited Cardiomyopathies.

Authors:  Giulia Frisso; Nicola Detta; Pamela Coppola; Cristina Mazzaccara; Maria Rosaria Pricolo; Antonio D'Onofrio; Giuseppe Limongelli; Raffaele Calabrò; Francesco Salvatore
Journal:  Int J Mol Sci       Date:  2016-11-10       Impact factor: 5.923

7.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.

Authors:  Patrick R Sosnay; Karen R Siklosi; Fredrick Van Goor; Kyle Kaniecki; Haihui Yu; Neeraj Sharma; Anabela S Ramalho; Margarida D Amaral; Ruslan Dorfman; Julian Zielenski; David L Masica; Rachel Karchin; Linda Millen; Philip J Thomas; George P Patrinos; Mary Corey; Michelle H Lewis; Johanna M Rommens; Carlo Castellani; Christopher M Penland; Garry R Cutting
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.